Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

Prior treatment

• Patients who have clinically significant edema or tumor mass effect requiring urgent intervention (e.g., surgery, initiation of steroids, escalating doses of steroids)
• Hemorrhagic or ischemic stroke (including transient ischemic attacks) and central nervous system bleeding in the preceding 6 months that are not related to glioma biopsy. History of prior intratumoral bleeding is not an exclusion criterion; however, all patient's navigation CTs will be reviewed for the presence of fresh blood.
• Participation in another interventional clinical trial during this trial or within 4 weeks before entry into this trial
• Unable to avoid photosensitising drugs (eg, St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones, and tetracyclines) for up to 2 weeks following 5-ALA administration
• Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g, clinically significant pulmonary disease, clinically significant psychiatric or neurological disorder, active or uncontrolled infection)

Other illness

• Hypersensitivity to 5-ALA or porphyrins
• Gastrointestinal disorder that negatively affects absorption
• Known active hepatitis B or C (Note: testing is not required)
• Known Human Immunodeficiency Virus (HIV) infection (Note: testing is not required)
• Diagnosis of other invasive cancer (except basal cell carcinoma/squamous cell carcinoma of the skin) within the last 5 years; adequately treated carcinoma in situ is allowed
• Patient has a condition the investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk

Other

• Infra-tentorial tumors
• Women who are pregnant or breastfeeding
• Inability to undergo MRI or receive gadolinium (Gd)
• Average skull thickness at the treatment field \> 10 mm from standard navigation CTs. The treatment field is defined as the various locations on the head where the transducer will be coupled to the patient. The average skull thickness at each treatment field will be determined through post-processing the thin cut head computed tomography (CT) scan (without contrast).
• Known acute or chronic types of porphyria
• Patients who are dependent on the sponsor, investigator or trial site
• Patients who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities

• Age ≥ 18 years
• WHO Performance Status of 0-2
• Patients with cranial MRI displaying typical features of high-grade glioma on imaging or histologically proven high-grade glioma including GBM, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO). No previous tumor specific treatment such as surgery (apart from biopsy), radio- or chemotherapy, antiangiogenic or immunotherapy.
• Planned debulking or cytoreductive surgery
• The following laboratory values at study entry
  • Absolute neutrophil count (ANC) ≥ 1500 cells/mm3
  • Platelet count ≥ 100,000 cells/mm3
  • Hemoglobin (Hgb) \> 10g/dL
  • AST and ALT ≤ 2.5 x Upper Limit of Normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN
  • Creatine clearance (CrCL) as estimated by Cockcroft-Gault equation of
  • ≥ 40 mL/min
  • Blood clotting within acceptable limits according to investigator
• For female and male patients and their female partners of childbearing/reproductive potential: Willingness to apply highly effective contraception (Pearl index \<1) during the entire study and in female patients for 6 months after the last application of Gliolan® and in male patients and their female partners for 3 months after the last application of Gliolan®.
• Ability to understand and provide informed consent